Mara Holton, MD
Urology · Annapolis, MDNPI 1275677874
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Johnson & Johnson at 29.2% of the total. 2025 is the largest year on record at $4,241, 5.0 times the $856 reported in 2019.
Across 147 payments — averaging $90.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Bayer$3K
- Verity Pharmaceuticals Inc.$1K
- Axonics, Inc.$794
- Urogen Pharma, Inc.$597
- Valencia Technologies Corporation$593
- plus $3K from 27 others
What the payments were for
- Consulting fees$6,17046%
- Speaking & faculty fees$1,0008%
- Travel & lodging$5634%
- Food & beverage$5,57742%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 15 | $3,881 |
| Bayer | 14 | $3,471 |
| Verity Pharmaceuticals Inc. | 1 | $1,000 |
| Axonics, Inc. | 31 | $794 |
| Urogen Pharma, Inc. | 15 | $597 |
| Valencia Technologies Corporation | 2 | $593 |
| AbbVie(2 entities) | 10 | $459 |
| Dendreon Pharmaceuticals LLC | 4 | $458 |
| Boston Scientific | 7 | $403 |
| Astellas Pharma US Inc | 8 | $291 |
| Ferring Pharmaceuticals Inc. | 7 | $147 |
| Pfizer | 4 | $147 |
| Myriad Genetic Laboratories, Inc. | 1 | $145 |
| Telix Pharmaceuticals | 2 | $137 |
| Sumitomo Pharma America, Inc. | 5 | $120 |
| Baxter Healthcare | 1 | $95 |
| Immunitybio, Inc. | 1 | $91 |
| Coloplast | 1 | $68 |
| Olympus America Inc. | 3 | $62 |
| Stryker | 1 | $52 |
| Myovant Sciences Inc. | 1 | $38 |
| Endo Pharmaceuticals Inc. | 2 | $34 |
| Tempus AI, Inc | 1 | $29 |
| Tolmar, Inc. | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $22 |
| Laborie Medical Technologies Corp. | 1 | $21 |
| Medtronic | 1 | $19 |
| Teleflex LLC | 1 | $19 |
| Amgen | 1 | $19 |
| Novartis | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Vertex | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- eCoin Device Kit$563
- PROVENGE$432
- Nubeqa$263
- ILLUCCIX$235
- Prolaris$145
- Erleada$144
- BOTOX$138
- Lupron Depot$124
- JELMYTO$124
- Axonics$111
How this compares
$13,310 in reported general payments places this provider in the 80th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 207 | $199,686 |
| MyrbetriqMirabegron | 51 | $45,800 |
| Fosfomycin Tromethamine | 13 | $10,302 |
| Estradiol | 140 | $10,193 |
| Tamsulosin Hcl | 99 | $2,244 |
| NitrofurantoinNitrofurantoin Macrocrystal | 46 | $1,948 |
| Solifenacin Succinate | 29 | $1,761 |
| Cephalexin | 89 | $1,259 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 76 | $1,080 |
| Methenamine Hippurate | 18 | $980 |
| Finasteride | 32 | $567 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $537 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 73 | $382 |
| Cefdinir | 19 | $314 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 11 | $196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $120 | $199,686207 claims |
| Astellas Pharma US IncMyrbetriq | $291 | $45,80051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 274 urology providers in Maryland.
Other urology in Annapolis
- Richard LevinAnnapolis$51K
- Juddson ChasonAnnapolis$20K
- Shaoqing ZhouAnnapolis$15K
- James MastersonAnnapolis$14K
- Christopher GrazianoAnnapolis$12K
- Matthew AllawayCumberland$20.6M
- Benjamin LowentrittBaltimore$549K
- Julio DavalosGlen Burnie$490K
- Sankar KausikBel Air$375K
- Laura GiustoOwings Mills$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.